Trial Profile
A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (TRIO-US L-07)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary) ; Temozolomide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 16 Nov 2023 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.
- 16 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 16 Nov 2023 Status changed from active, no longer recruiting to recruiting.